These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26048121)

  • 1. [Not Available].
    Gruell H; Klein F
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():46-9. PubMed ID: 26048121
    [No Abstract]   [Full Text] [Related]  

  • 2. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
    Ahmad M; Ahmed OM; Schnepp B; Johnson PR
    Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies.
    Gruell H; Klein F
    Nat Med; 2014 May; 20(5):478-9. PubMed ID: 24804756
    [No Abstract]   [Full Text] [Related]  

  • 4. Report of the 2014 Cent Gardes HIV Vaccine Conference - Part 1: Neutralizing Antibodies; Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October 2014.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2015 Jul; 33(31):3605-8. PubMed ID: 25769208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges.
    Liu ZJ; Bai J; Liu FL; Zhang XY; Wang JZ
    Int Immunopharmacol; 2017 Nov; 52():44-50. PubMed ID: 28858725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly Neutralizing Antibodies and the Development of Vaccines.
    Haynes BF; Bradley T
    JAMA; 2015 Jun 23-30; 313(24):2419-20. PubMed ID: 26103022
    [No Abstract]   [Full Text] [Related]  

  • 7. Natural infection as a blueprint for rational HIV vaccine design.
    van Haaren MM; van den Kerkhof TL; van Gils MJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):229-236. PubMed ID: 27649455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current world literature.
    Curr Opin HIV AIDS; 2009 Sep; 4(5):453-7. PubMed ID: 20046137
    [No Abstract]   [Full Text] [Related]  

  • 10. [Trispecific broadly neutralizing antibodies for HIV immunoprophylaxis and immunotherapy?].
    Barin F; Stefic K
    Med Sci (Paris); 2018 Feb; 34(2):109-111. PubMed ID: 29451475
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.
    Klein F; Halper-Stromberg A; Horwitz JA; Gruell H; Scheid JF; Bournazos S; Mouquet H; Spatz LA; Diskin R; Abadir A; Zang T; Dorner M; Billerbeck E; Labitt RN; Gaebler C; Marcovecchio P; Incesu RB; Eisenreich TR; Bieniasz PD; Seaman MS; Bjorkman PJ; Ravetch JV; Ploss A; Nussenzweig MC
    Nature; 2012 Dec; 492(7427):118-22. PubMed ID: 23103874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of broadly neutralizing antibodies for HIV-1 prevention.
    Pegu A; Hessell AJ; Mascola JR; Haigwood NL
    Immunol Rev; 2017 Jan; 275(1):296-312. PubMed ID: 28133803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2017 Keystone Symposium on HIV Vaccines.
    Cottrell CA; Ward AB
    Hum Vaccin Immunother; 2017 Oct; 13(10):2348-2351. PubMed ID: 28786733
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted Immune Interventions for an HIV-1 Cure.
    Perreau M; Banga R; Pantaleo G
    Trends Mol Med; 2017 Oct; 23(10):945-961. PubMed ID: 28890135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-mediated prevention and treatment of HIV-1 infection.
    Gruell H; Klein F
    Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making it to manufacturing. The potential success of broadly neutralizing monoclonal antibodies for HIV prevention, treatment, and possibly even a cure could come at a cost.
    Dumiak M
    IAVI Rep; 2014; 18(2):4-7, 17. PubMed ID: 25105201
    [No Abstract]   [Full Text] [Related]  

  • 19. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial suggests vaccines could aid HIV therapy.
    Check E
    Nature; 2003 Apr; 422(6933):650. PubMed ID: 12700722
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.